Human embryonic stem cell-derived cardiomyocyte platform screens inhibitors of SARS-CoV-2 infection
Published version
Peer-reviewed
Repository URI
Repository DOI
Type
Change log
Authors
Abstract
Abstract: Patients with cardiovascular comorbidities are more susceptible to severe infection with SARS-CoV-2, known to directly cause pathological damage to cardiovascular tissue. We outline a screening platform using human embryonic stem cell-derived cardiomyocytes, confirmed to express the protein machinery critical for SARS-CoV-2 infection, and a SARS-CoV-2 spike-pseudotyped virus system. The method has allowed us to identify benztropine and DX600 as novel inhibitors of SARS-CoV-2 infection in a clinically relevant stem cell-derived cardiomyocyte line. Discovery of new medicines will be critical for protecting the heart in patients with SARS-CoV-2, and for individuals where vaccination is contraindicated.
Description
Funder: Cambridge Biomedical Research Centre Biomedical Resources Grant (University of Cambridge, Cardiovascular Theme RG64226
Keywords
Journal Title
Conference Name
Journal ISSN
Volume Title
Publisher
Publisher DOI
Sponsorship
British Heart Foundation (BHF) (FS/17/61/33473, TAF 03, RM/17/2/33380, TAF 03, FS/17/61/33473, FS/18/46/33663, RM/17/2/33380)